Jeremy Bastid

18 December 2020

Armand Bensussan awarded the Galien Prize 2020

Professor Martine Bagot and Professor Armand Bensussan are rewarded for their research on the development of a targeted therapy, lacutamab, a monoclonal antibody targeting the tumor antigen KIR3DL2 for the treatment of patients with advanced, refractory and relapsed T cell lymphomas, particularly erythrodermic cutaneous T cell lymphomas. The Galien Prize here rewards two decades of research.
17 December 2020

AACR annual meeting 2021

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.
15 December 2020

Season’s greetings

From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !
16 October 2020

Anti CD39 mAb IPH5201 at EMSO 2020

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. Download abstract.
Anti CD39 mAb IPH5201 at EMSO 2020
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more